Czech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotsThe Czech Republic wants to buy around 2.4 million doses of the AstraZeneca/Oxford University vaccine ditched by Denmark, Share XCzech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotshttps://pharmaphorum.com/news/czech-republic-swoops-for-denmarks-2-4m-unwanted-az-covid-shots/
Romark eyes FDA okay for COVID antiviral despite mixed trial resultsA phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 Share XRomark eyes FDA okay for COVID antiviral despite mixed trial resultshttps://pharmaphorum.com/news/romark-eyes-fda-okay-for-covid-antiviral-despite-mixed-trial-results/
Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
Fernandez and Loveya take senior roles at FCB HealthConsumer advertising guru Humberto Fernandez has joined FCB Health as group creative director, with Anna Loveya joining the Share XFernandez and Loveya take senior roles at FCB Healthhttps://pharmaphorum.com/news/fernandez-and-loveya-take-senior-roles-at-fcb-health/
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of Share XPfizer/Myovant take relugolix contraceptive combination pill into phase 3https://pharmaphorum.com/news/pfizer-myovant-take-relugolix-contraceptive-combination-pill-into-phase-3/
Gilead’s Trodelvy approved in metastatic urothelial cancerGilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Share XGilead’s Trodelvy approved in metastatic urothelial cancerhttps://pharmaphorum.com/news/gileads-trodelvy-approved-in-metastatic-urothelial-cancer/
AI device cleared by FDA to spot lesions during colonoscopyThe FDA has approved the first artificial intelligence-powered device that can be used to help identify colorectal lesions Share XAI device cleared by FDA to spot lesions during colonoscopyhttps://pharmaphorum.com/news/ai-device-cleared-by-fda-to-spot-lesions-during-colonoscopy/
AZ aims at Pfizer, GSK with potential new PARP cancer drugAstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in Share XAZ aims at Pfizer, GSK with potential new PARP cancer drughttps://pharmaphorum.com/news/az-aims-at-pfizer-gsk-with-potential-new-parp-cancer-drug/
Update: J&J COVID vaccine rollout paused as clot concerns spreadUS health authorities have recommended pausing dosing with Johnson & Johnson’s COVID-19 vaccine as they investigate cases of Share XUpdate: J&J COVID vaccine rollout paused as clot concerns spreadhttps://pharmaphorum.com/news/us-seeks-halt-on-jj-covid-vaccine-rollout-as-clot-concerns-spread/
England begins Moderna vaccine rollout as lockdown easesEngland is beginning its rollout of the Moderna COVID-19 vaccine, offering an alternative to the AstraZeneca/Oxford University jab Share XEngland begins Moderna vaccine rollout as lockdown easeshttps://pharmaphorum.com/news/england-begins-moderna-vaccine-rollout-as-lockdown-eases/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
Akari begins late-stage trial of nomacopan for Bullous PemphigoidAkari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare Share XAkari begins late-stage trial of nomacopan for Bullous Pemphigoidhttps://pharmaphorum.com/news/akari-begins-late-stage-trial-of-nomacopan-for-bullous-pemphigoid/
Apple, Google block NHS contact tracing app update on privacy groundsA scheduled update to the NHS COVID-19 app has been blocked because it allows location tracking – something Share XApple, Google block NHS contact tracing app update on privacy groundshttps://pharmaphorum.com/news/apple-google-block-nhs-contact-tracing-app-update-on-privacy-grounds/
Fishawack buys health economics consultancy PRMAUK comms agency Fishawack Health has acquired the health economics outcomes research (HEOR) consultancy PRMA Consulting. PRMA has Share XFishawack buys health economics consultancy PRMAhttps://pharmaphorum.com/news/fishawack-buys-health-economics-consultancy-prma/
South African variant may evade Pfizer/BioNTech vaccine, study findsThe coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted Share XSouth African variant may evade Pfizer/BioNTech vaccine, study findshttps://pharmaphorum.com/news/south-african-variant-may-evade-pfizer-biontech-vaccine-study-finds/
Regeneron’s antibody cocktail hits target in COVID prevention studyRegeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for Share XRegeneron’s antibody cocktail hits target in COVID prevention studyhttps://pharmaphorum.com/news/regeneron-to-ask-fda-to-c/
AstraZeneca’s Farxiga fails phase 3 COVID-19 testHope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed Share XAstraZeneca’s Farxiga fails phase 3 COVID-19 testhttps://pharmaphorum.com/news/astrazenecas-farxiga-fails-phase-3-covid-19-test/
KOL Mindset Mapping Share XKOL Mindset Mappinghttps://pharmaphorum.com/partner-content/kol-mindset-mapping/
J+D Forecasting provides Online Team Pharma Forecasting Training Share XJ+D Forecasting provides Online Team Pharma Forecasting Traininghttps://pharmaphorum.com/partner-content/jd-forecasting-provides-online-team-pharma-forecasting-training/
Continuity of Care in a Pandemic: Reflecting on the Rise of Telehealth Share XContinuity of Care in a Pandemic: Reflecting on the Rise of Telehealthhttps://pharmaphorum.com/partner-content/continuity-of-care-in-a-pandemic-reflecting-on-the-rise-of-telehealth/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
Prescient Announces Recent Appointments to its Senior Team Share XPrescient Announces Recent Appointments to its Senior Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/
